Drug Eluting Stent News and Research

RSS
A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
Reva Medical commences its first clincial trial

Reva Medical commences its first clincial trial

Drug-coated balloon restores blood flow in narrowed bare metal stent

Drug-coated balloon restores blood flow in narrowed bare metal stent

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell announces preliminary data from MiStent Sirolimus DES clinical study

DSM and Svelte Medical Systems enter into license and supply agreement

DSM and Svelte Medical Systems enter into license and supply agreement

Medtronic highlights scientific sessions of interest on program for TCT 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

HCRI completes enrollment in dual antiplatelet therapy clinical trial

HCRI completes enrollment in dual antiplatelet therapy clinical trial

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Everolimus-eluting stent and SES are equally effective for PCI patients

Everolimus-eluting stent and SES are equally effective for PCI patients

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent